Richard Menziuso was named Vice President, Global Controller and Principal Accounting of Altimmune, Inc., effective September 29, 2026. As of October 28, 2026, Altimmune, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from September 29, 2026 to October 27, 2026, naming 1 appointment (Form 8-K, September 29, 2026).
Sell to companies like Altimmune, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Altimmune, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-09-29 to 2026-10-27. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Altimmune, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-27 | Reported | not named in the filing | 8-K, 2026-10-27 | ||
| 2026-09-29 | In | Vice President, Global Controller and Principal Accounting | 2026-09-29 | 8-K, 2026-09-29 |
Selling to them or working with them? See who runs Altimmune, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Altimmune, Inc. and the records around it.
Altimmune, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Who owns it
Companies that share a holder
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026), Inhibrx Biosciences, Inc. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 32 other companies: Skye Bioscience, Inc. (Oct 2026), Atea Pharmaceuticals, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Watch Altimmune, Inc.
Get an email when Altimmune, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Altimmune, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Altimmune, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Altimmune, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Altimmune, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Vice President, Global Controller and Principal Accounting: Richard Menziuso, appointed, effective 2026-09-29 (filed 2026-09-29).
New leaders reset buying decisions — get the Full Report on Altimmune, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Vice President, Global Controller and Principal Accounting at Altimmune, Inc., with the record behind each one.
Find candidates like Global Controller and Principal Accounting at Altimmune, Inc.Every change, in the filing's words
Reported
On October 23, 2026, each of John Gill, Mitchell Sayare and Dr. Klaus Schafer notified the Board of Directors (the "Board") of Altimmune, Inc. (the "Company"), of his decision to retire and not stand for re-election to the Board at the Company's 2027 annual meeting of stockholders (the "2027 Annual Meeting").
Appointed: Richard Menziuso, Vice President, Global Controller and Principal Accounting, effective 2026-09-29
On September 24, 2026, the Board of Directors (the "Board") of Altimmune, Inc. (the "Company") appointed Richard Menziuso as the Company's Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2026.
Tools for this story
Each opens in a new tab, filled in for Altimmune, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.